Abstract
Background
Third-line antidiabetic drug (ADD) intensification patterns and glycemic control post intensification in type 2 diabetes mellitus (T2DM) have not been thoroughly explored in a real-world setting.
Objective
This study explored the patterns and risks of third-line ADD intensification post second-line ADDs and the probability of desirable glucose control over 12 months by third-line ADD classes at the population level.
Methods
We used the electronic medical records of 255,236 patients with T2DM in the USA initiating a second-line ADD post metformin from January 2013 to evaluate the rates and risks of third-line intensification and the probability of desirable glycemic control with different ADDs after addressing inherent heterogeneity using appropriate methodologies.
Results
Patients had a mean age of 60 years and glycated hemoglobin (HbA1c) of 8.5% at second-line ADD. Over 209,136 person-years (PY) of follow-up, 40% had initiated a third-line ADD at HbA1c of 8.8%. Patients receiving dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as the second-line ADD had a 7% (95% hazard ratio [HR] confidence interval [CI] 1.05–1.10) and 28% (95% HR CI 1.24–1.33) higher adjusted risk of intensifying with a third-line ADD than did those receiving sulfonylureas as the second-line ADD. Those receiving sodium-glucose cotransporter-2 inhibitors (SGLT-2i) as second-line ADD had a 17% (95% HR CI 0.80–0.87) lower risk. The adjusted probability of reducing HbA1c by ≥ 1% was similar in those receiving third-line sulfonylureas, thiazolidinediones, GLP-1 RAs, SGLT-2i, and insulin (minimum, maximum 95% CI of probability 0.61, 0.68), whereas those receiving DPP-4i had a significantly lower probability (0.58; 95% CI 0.56–0.59). Similarly, the probability of reducing HbA1c < 7.5% was similar in the sulfonylurea, GLP-1 RA, and SGLT-2i groups (minimum, maximum of 95% CI of probability 0.41, 0.49), whereas those receiving DPP-4i had a significantly lower probability of achieving an HbA1c < 7.5% (0.37; 95% CI 0.36–0.38).
Conclusion
This study, based on a large representative cohort of patients with T2DM from the USA, suggests the need for revisiting real-world practices in choosing therapeutic intensification pathways and a more proactive strategy to tackle the persistent risk factor burden in patients with T2DM.
Similar content being viewed by others
References
American Diabetes Association. Summary of revisions: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S4–6.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98.
Weiss T, Iglay K, Carr RD, Mishra AP, Yang L, Rajpathak S. 984-P: real-world adherence and discontinuation of GLP-1 receptor agonist (GLP-1RA) therapy in type 2 diabetes (T2D) patients in the US. Diabetes. 2019;68(Supplement 1):984-P.
Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the US: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78.
Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes—update. Ottawa: The Agency; 2013.
Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes—update. Ottawa: The Agency; 2013.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7.
Levin PA, Wei W, Zhou S, Xie L, Baser O. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. J Manag Care Sp Pharm. 2014;20(5):501–12.
Canivell S, Mata-Cases M, Real J, Franch-Nadal J, Vlacho B, Khunti K, et al. Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting. Diabetes Obes Metab. 2019;21(6):1373–80.
Segal JB, Maruthur NM. Initial therapy for diabetes mellitus. JAMA Intern Med. 2014;174(12):1962–3.
Crawford AG, Cote C, Couto J, Daskiran M, Gunnarsson C, Haas K, et al. Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States. Popul Health Manag. 2010;13(3):139–50.
Montvida O, Klein K, Kumar S, Khunti K, Paul SK. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: a real-world study in 66 583 patients. Diabetes Obes Metab. 2017;19(1):108–17.
Paul SK, Shaw JE, Montvida O, Klein K. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(12):1244–52.
Owusu Adjah ES, Montvida O, Agbeve J, Paul SK. Data mining approach to identify disease cohorts from primary care electronic medical records: a case of diabetes mellitus. Open Bioinform J. 2017;10(1):16–27.
Montvida O, Arandjelović O, Reiner E, Paul SK. Data mining approach to estimate the duration of drug therapy from longitudinal electronic medical records. Open Bioinform J. 2017;10:1–15.
Thomas G, Klein K, Paul S. Statistical challenges in analysing large longitudinal patient-level data: the danger of misleading clinical inferences with imputed data. J Indian Soc Agric Stat. 2014;68:39–54.
Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23(19):2937–60.
McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9(4):403.
Montvida O, Shaw JE, Blonde L, Paul SKJD. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: a real-world study. Obesity Metab. 2018;20(7):1722–31.
Montvida O, Cai X, Paul SK. Cardiovascular risk factor burden in people with incident type 2 Diabetes in the US receiving antidiabetic and cardioprotective therapies. Diabetes Care. 2019;42(4):644–50.
Thewjitcharoen Y, Yenseung N, Malidaeng A, Nakasatien S, Chotwanvirat P, Krittiyawong S, et al. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. Diabetol Metab Syndr. 2017;9:96.
Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, et al. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes Obes Metab. 2018;20(2):389–99.
Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L, et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 2018;16(1):116.
Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–9.
Kim SG, Kim NH, Ku BJ, Shon HS, Kim DM, Park TS, et al. Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): a prospective observational DIPP-FACTOR study in Korea. J Diabetes Investig. 2017;8(3):346–53.
Khunti K, Gomes MB, Pocock S, Shestakova MV, Pintat S, Fenici P, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427–37.
Zaccardi F, Dhalwani NN, Dales J, Mani H, Khunti K, Davies MJ, et al. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(4):985–97.
Montvida O, Shaw JE, Blonde L, Paul SK. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: a real-world study. Diabetes Obes Metab. 2018;20(7):1722–31.
Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40(11):1425–32.
Loughlin AM, Qiao Q, Nunes AP, Ezzy SM, Yochum L, Clifford CR, et al. Effectiveness and tolerability of therapy with once-weekly exenatide versus basal insulin among injectable-naive patients with type 2 diabetes in a real-world setting in the United States. Diabetes Spectr. 2018;31(2):129–37.
Mata-Cases M, Franch-Nadal J, Real J, Gratacos M, Lopez-Simarro F, Khunti K, et al. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment. Diabetes Obes Metab. 2018;20(1):103–12.
Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, et al. Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes. Diabetes Care. 2018;41(10):2096–104.
Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, de Zeeuw D, Stolk RP, Denig P. Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus–a cohort study. PLoS One. 2012;7(6):e38707.
Acknowledgements
DNK, OM, and SKP were responsible for the primary design of the study. OM extracted the data. DNK and SKP jointly conducted the statistical analyses. The first draft of the manuscript was developed by DNK and SKP, and all authors contributed to the finalization of the manuscript. SKP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Melbourne EpiCentre gratefully acknowledges the support from the National Health and Medical Research Council and the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) initiative through Therapeutic Innovation Australia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this manuscript was not supported by any external funding.
Conflicts of interest
SKP has acted as a consultant and/or speaker for Novartis, GI Dynamics, Roche, AstraZeneca, Sanofi, Guangzhou Zhongyi Pharmaceutical, and Amylin Pharmaceuticals LLC. He has received grants in support of investigator and investigator-initiated clinical studies from Merck, Novo Nordisk, AstraZeneca, Hospira, Amylin Pharmaceuticals, Sanofi, and Pfizer. DNK and OM have no conflicts of interest that are directly relevant to the content of this article.
Rights and permissions
About this article
Cite this article
Koye, D.N., Montvida, O. & Paul, S.K. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study. Drugs 80, 477–487 (2020). https://doi.org/10.1007/s40265-020-01279-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-020-01279-y